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Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious 
potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading 
to an increase in the channel open probability through a set of changes in the open and closed time distributions. The en-
dogenous  neurosteroid  allopregnanolone  potentiates  the  α1β2γ2L  GABA-A  receptor  by  enhancing  the  mean  
duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived  
intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is 
decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and 
steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the 
GABA-A  receptor  through  interactions  with  the  membrane-spanning  region  of  the  receptor.  However,  the  number  
of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. 
multiple sites mediating the potentiating actions of steroids. 
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INTRODUCTION 
  Neurosteroids are synthesized in the central and periph-
eral nervous system from cholesterol or other steroidal pre-
cursors [9, 14, 31]. The enzymes required for neurosteroi-
dogenesis are present in oligodendrocytes and astrocytes as 
well as at least some types of neurons [29, 38, 41]. The neu-
rosteroids synthesized in and secreted from glial cells act as 
paracrine  messengers. In the case of neuronal neurosteroi-
dogenesis the neurosteroids may act locally on their targets 
through an autocrine mechanism [1]. 
  From a viewpoint of medicinal chemistry, the steroid ring 
structure serves as a useful pharmacophore template to create 
synthetic neuroactive steroid analogs. There are two general 
motivations for such work. First, studies on structure-activity 
relationships  can  yield  novel  information  on  the  function  
and modulation of the target receptor, and second, the studies 
can  help  generate  receptor  subtype-specific  compounds  
with  therapeutic  potential.  Indeed,  ongoing  interest  in  the 
study  and  development  of  potentiating  steroids  is  driven  
by  the  behavioral  effects  of  endogenous  steroids  and  the  
potential therapeutic use of exogenous steroid analogs [17, 
30]. 
  Neurosteroids and synthetic steroid analogs have multi-
ple targets in the brain. These include transmitter-gated ion 
channels  such  as  the  GABA-A  and  NMDA  receptors  [28, 
39]. Steroids can also modulate some voltage-gated calcium  
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channels  thereby  modifying  transmitter  release  [18]  or  
altering pain threshold in animal models [37]. Other cellular 
processes  modulated  by  neurosteroids  are  microtubule  
assembly  affecting  neural  cytoskeleton  dynamics  [16]  and 
regulation of cell death [12]. 
  The GABA-A receptor is an anion-selective pentameric 
receptor-channel whose activation in most cases has an in-
hibitory influence on the cell. Accordingly, drugs capable of 
potentiating the GABA-A receptor activity can be useful as 
anesthetics,  anticonvulsants  and  anxiolytics.  Many  neuros-
teroids are potent and efficacious modulators of the GABA-
A receptor. It is likely that GABA-A receptors in vivo are 
under tonic, but submaximal neurosteroid modulatory con-
trol [10, 26]. The nature of modulation can be inhibitory or 
potentiating, depending on the structure of the steroid. Typi-
cally, steroids containing charged groups (e.g., pregnenolone 
sulfate)  act  as  inhibitors  of  the  GABA-A  receptor.  Most  
potentiating  steroids  also  directly  activate  the  GABA-A  
receptor when used at high concentrations. It is likely that 
inhibition, potentiation, and direct activation are mediated by 
steroid interactions with distinct sites [3, 20, 21, 33, 34]. In 
this  review,  we  discuss  the  kinetic  and  structural  features 
underlying the rat α1β2γ2L GABA-A receptor potentiation 
by endogenous neurosteroids and synthetic steroid analogs. 
We focus on the published work from our laboratories and 
introduce some novel, previously unpublished data. 
KINETIC  MECHANISMS  OF  ACTION  OF  POTEN-
TIATING STEROIDS 
  In  whole-cell  recordings,  coapplication  of  potentiating 
neurosteroids with agonist leads to enhancement of the peak 
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on the concentration of agonist used to activate the receptors, 
the effect is greater in the presence of lower concentrations 
of agonist. At 5 µM GABA (~EC20), exposure of α1β2γ2L 
GABA-A receptors expressed in human embryonic kidney 
cells  to  high  concentrations  of  neurosteroids  such  as  allo-
pregnanolone elicits an approximately 3-4-fold potentiation 
of peak response [26].  
  Single-channel currents recorded at high GABA concen-
trations  (EC20  and  above)  exhibit  characteristic  "single-
channel  clusters",  i.e.,  episodes  of  high-frequency  activity 
originating from a single receptor [25, 36]. Clusters contain a 
wealth of information about the activation properties of the 
receptor;  most  importantly,  the  kinetic  studies  on  single-
channel  clusters  allow  one  to  focus  on  the  actions  of  the 
modulator on a single receptor and eliminate the ambiguity 
about changes in the number of active receptors or single-
channel conductance.  
  The  open  and  closed  time  histograms  generated  from 
single-channel clusters from the α1β2γ2L GABA-A receptor 
each  contain three components (e.g., [36]). The open  time 
distributions are generally not affected by changes in GABA 
concentration  indicating  that  the  majority  of  openings  at 
these GABA concentrations (i.e., above EC20) originate from 
fully-liganded receptors. The mean durations and prevalence 
of  two  of  the  closed  time  components  remain  unchanged 
throughout a wide range of GABA concentrations. We pre-
viously proposed that the states producing these closed time 
components are not on the return pathway to the resting re-
ceptor [36]. The mean duration of the third component in the 
closed time histograms scales with agonist concentration (it 
is briefer when higher concentrations of GABA are used to 
activate  the  receptor).  This  closed  time  component  likely 
reflects steps in the channel activation pathway, i.e., transi-
tions from the unliganded, closed state to the fully-liganded 
open state.  
  Work on GABA-A receptor single-channel activity has 
shown  that  steroid-elicited  potentiation  results  from  en-
hanced open probability (Po) of the receptor, not changes in 
single-channel conductance or the number of active recep-
tors. The increase in open probability in the presence of po-
tentiating steroids results from specific changes in the chan-
nel open and closed time distributions (Fig. 1B). Overall, the 
mean open duration of the channel is increased and the mean 
closed time duration is decreased. The prolongation of the 
mean open time results from two specific changes in receptor 
kinetics. First, the mean duration of the longest of the three 
open time components (OT3) is increased. In the presence of 
GABA alone, the mean duration of OT3 is 6-7 ms [26, 36]. 
When high concentrations of potentiating steroids are coap-
plied with GABA the mean duration of OT3 is increased to 
15-25 ms [3, 7]. Second, the relative frequency of OT3 in-












Fig. (1). Potentiation of the α1β2γ2L GABA-A receptor by allopregnanolone. (A) Whole-cell recordings from a HEK cell expressing 
wild-type α1β2γ2L GABA-A receptors. The cell was exposed to 5 µM GABA in the absence and presence of 1 µM allopregnanolone. 5 µM 
GABA corresponds to approximately EC20 in the activation concentration-effect curve. 1 µM allopregnanolone corresponds to a maximally 
potentiating concentration. (B) Sample single-channel currents from cell-attached patches exposed to 50 µM GABA (top trace) or GABA + 1 
µM allopregnanolone (bottom trace). Openings are shown as downward deflections. The open and closed time histograms from the respec-
tive patches are shown next to the data traces. Only single-channel clusters, i.e., data resulting from the activation of a single receptor-
channel, were used in the analysis. Allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and preva-
lence of the longest of the three open time components (red line in open time histograms) and reducing the prevalence of the longest of the 
three intracluster closed time components (red line in closed time histograms). For GABA, the open times were 0.11 ms (21 %), 2.8 ms (75 
%) and 8 ms (4 %), and the closed times were 0.14 ms (64 %), 1 ms (13 %) and 12 ms (22 %). For GABA + allopregnanolone, the open 
times were 0.39 ms (32 %), 2.8 ms (32 %) and 12 ms (35 %), and the closed times were 0.12 ms (83 %), 1 ms (14 %) and 10 ms (3 %). The 
data shown in the figure have not been published previously. 20    Current Neuropharmacology, 2010, Vol. 8, No. 1  Akk et al. 
centrations of steroids, i.e., the long openings become more 
prevalent. The reduction in the mean intracluster closed time 
duration in the presence of potentiating steroids is the result 
of a selective reduction in the prevalence of the longest-lived 
closed  time  component  (CT3).  The  prevalence  of  CT3  is 
approximately  25  %  in  the  presence  of  GABA  [36].  This 
value is reduced to 3-10 % in the presence of potentiating 
steroids [3, 23].  
  All three kinetic effects contribute to the overall poten-
tiating  effect,  however  the  relative  contributions  are  not 
equal. Fig. (2) shows the calculated contributions from the 
individual components to the total, overall potentiation. The 
calculations are based on our single-channel work on the rat 
α1β2γ2L GABA-A receptor [3, 36] and were carried out at a 
GABA concentration producing 20 % of maximal response. 
The range of steroid effects on the open and closed times 
was  held  to  that  measured  for  allopregnanolone  [26].  Ac-
cording to the calculations the peak response at 1 µM steroid 
is 340 % of control (no effect equals 100 %). This value is 
similar to the experimental findings on whole-cell potentia-
tion by allopregnanolone (range of 346 - 438 %; [25, 26]. 
The  graph  indicates  that  the  greatest  contribution  to  total 
potentiation is made by the steroid effect on the closed time 
distribution. If only this parameter was modified by the ster-
oid, the relative response would be 238 % of control. Steroid 
effects on the mean duration and prevalence of OT3 make 
smaller  contributions  to  the  overall  potentiation.  Receptor 
responses would be 121 and 126 % of control if the steroid 
affected solely the mean duration or prevalence of the long-
est-lived open time component, respectively. 
  The pattern of three kinetic effects triggered by steroids 
as described above is typical for many neuroactive steroids 
including allopregnanolone [7], pregnanolone [24], and the 
synthetic  steroid  analog  (3α,5α,17β)-3-hydroxyandrostane-
17-carbonitrile  [3].  On  the  other  hand,  some  neuroactive 
steroids selectively affect a subset of kinetic parameters. For 
example, the endogenous steroid  etiocholanolone i ncreases 
the prevalence of long openings without affecting the mean 
duration  of  long  openings  or  the  closed  time  distributions 
[24]. As expected based on the analysis presented in Fig. (2), 
the overall potentiating effect of etiocholanolone  as meas-
ured  in  whole-cell  recordings  is  relatively  weak  [22,  24]. 
Furthermore, cyclopenta[b]phenanthrenes and cyclopenta[b] 
anthracenes, tetracyclic molecules with ring systems differ-
ent  from  that  of  steroids,  have  been  shown  to  selectively 
modify receptor kinetics [33], but the relationship between 
the ring system and kinetic parameters affected by the drug 
is unclear at the moment. 
  Despite  extensive  kinetic  studies,  relatively  little  is 
known about which molecular processes or kinetic rate con-
stants are affected by steroids. In part this is due to the com-
plex kinetic properties of the GABA-A receptor and the lack 
of  a  commonly  accepted  kinetic  model  for  its  activation. 
Nevertheless, several conclusions regarding the mechanisms 












Fig. (2). Total potentiation by steroids is dominated by the effect on the prevalence of long intracluster closed times. The curves show 
total potentiation (black line) and potentiation under conditions where only the duration (green) or prevalence of long openings (blue), or the 
prevalence of long closed times (red) is affected by the steroid. The calculations were carried out based on the Po and effective opening  
rate data from the rat α1β2γ2L receptor expressed in HEK cells [33]. The dashed line represents control response. The steroid effect was 
calculated in the presence of EC20 GABA, and the extent of steroid effect on each of the kinetic parameters was held similar to that seen  
in the presence of 1 µM allopregnanolone [24]. The mean duration of OT3 was 7.3 ms in the absence of steroid and 14.1 ms in the presence 
of a saturating concentration of steroid. The prevalence of OT3 was 13 % in the absence of steroid and 38 % in the presence of a saturating 
concentration of steroid. The prevalence of CT3 was 27 % in the absence of steroid and 5 % in the presence of a saturating concentration of 
steroid. The EC50-s for each of the kinetic effects of the steroid were held at 100 nM. The data shown in the figure have not been published 
previously. Kinetic and Structural Determinants for GABA-A Receptor Potentiation  Current Neuropharmacology, 2010, Vol. 8, No. 1    21 
specific kinetic model. For example, we suggest that poten-
tiating steroids do not affect receptor affinity to GABA or 
the channel opening rate constant. This conclusion is based 
on the finding that the channel effective opening rate curve is 
unaltered in the presence of steroids [3]. The effective open-
ing rate, which is defined as an inverse of the agonist con-
centration-dependent  closed  time  component  (please  see 
above), is dependent on receptor affinity to the agonist and 
the channel opening rate constant in the presence of a given 
agonist. Identical effective opening rate curves are thus an 
indication of identical affinity and channel opening proper-
ties.  
  The extent of receptor potentiation depends on the con-
centration of GABA at which the effect is measured. In gen-
eral, potentiation caused by changes in kinetics is limited to 
an open probability of 1. The α1β2γ2L GABA-A receptor 
has a maximal single-channel open probability of approxi-
mately 0.9, hence little potentiation can be seen at high or 
saturating  concentrations  of  GABA.  In  the  presence  of  a 
concentration of GABA eliciting 20 % of maximal response, 
neurosteroids such as allopregnanolone can produce 3-4-fold 
potentiation of the peak whole-cell response. At lower con-
centrations  of  GABA  the  degree  of  potentiation  increases 
due  to  expanded  dynamic  range  (e.g.,  [11]).  For  example, 
when 0.5 µM GABA (~EC5) is used to activate the receptor 
potentiation  by  saturating  concentrations  of  steroids  can 
reach 20-fold [24]. 
  GABA-A receptors containing the δ subunit are consid-
ered to be highly sensitive to potentiating steroids. The un-
derlying reason for this does not lie in the improved interac-
tions of steroids with such receptors. Rather it is caused by 
the low gating efficacy of the δ subunit-containing receptor. 
The α1β2δ and α4β2δ receptors are only weakly activated by 
GABA. The maximal open probability of these receptors in 
the presence of GABA  is very low, probably <0.1 [2, 15, 
40].  As  a  result,  the  dynamic  range  for  potentiation  is  
enhanced.  These  receptors  appear  to  be  more  strongly  
modulated by steroids and can show potentiation even when 
exposed to saturating GABA concentrations.  
LOCATION OF  BINDING SITES FOR POTENTIAT-
ING STEROIDS 
  Work from several laboratories has led to a conclusion 
that the binding sites for potentiating steroids are located in 
the membrane-spanning regions of the GABA-A receptor [7, 
19, 26, 32].  By employing single-channel patch clamp re-
cordings we showed that receptors in cells pretreated with a 
neuroactive steroid that was subsequently removed from the 
bath remained potentiated for long periods of time. Further-
more, receptors in patches excised from such cells remained 
potentiated  suggesting  that  the  steroid  accumulated  in  the 
cell membrane and was capable of eliciting potentiation even 
after patch excision [7]. In macroscopic whole-cell record-
ings the effect manifests as slow deactivation upon the re-
moval of the steroid and agonist from the bath.  
  To exclude the possibility that the slow washout of ster-
oid effect results from slow unbinding of the steroid from the 
receptor, we examined the effect of cyclodextrins on the de-
activation  rate.  Cyclodextrins  are  membrane-impermeant 
cyclic sugar molecules that can act as steroid scavengers by 
forming  an  inclusion  complex  with  the  steroid  [27,  35]. 
Thus, cyclodextrins can be used to reduce the concentration 
of free steroid in the membrane. We found that the inclusion 
of cyclodextrins in the bath during the washout phase drasti-
cally enhanced the deactivation rate [7, 13, 35]. This indi-
cates  that the  long-lasting potentiating effect of steroids  is 
dominated not by their slow dissociation from the receptor 
but rather by the retention of steroids in the membrane where 
they presumably act locally on the receptor. 
  By exploiting the difference in the ability of steroids to 
potentiate  insect  and  mammalian  GABA  receptors,  Hosie 
and coworkers [20] showed that steroid sensitivity correlated 
with  the structures of  the  M1  and  M4 transmembrane do-
mains of  the  α subunit. A chimeric approach followed by 
site-directed mutagenesis of residues in these regions helped 
to identify specific residues that were proposed to interact 
via hydrogen bonding with the C3 hydroxyl (α1Q241 in M1) 
and C20 ketone groups (α1N407 and Y410 in M4) of the 
neurosteroid  allopregnanolone.  Mutations  eliminating  the 
hydrogen  bonding  capability  of  these  residues  drastically 
reduced  or  abolished  potentiation  by  several  potentiating 
neurosteroids without affecting potentiation by other classes 
of  potentiators  such  as  barbiturates  or  benzodiazepines  
[20].  
HOW MANY SITES ARE ON THE GABA-A RECEP-
TOR FOR POTENTIATING STEROIDS? 
  The number of interaction sites mediating GABA-A re-
ceptor  potentiation  by  neuroactive  steroids  is  not  entirely 
clear at present. Although steroids can have multiple kinetic 
effects  on  channel  function,  the  effects  do  not  necessarily 
have to be mediated by distinct sites. A single interaction site 
could  mediate  multiple  kinetic  actions.  The  electrophysi-
ological  and molecular biological  approaches have yielded 
conflicting evidence, some of which support the notion of a 
single interaction sites for steroids. Other data are best ac-
counted  for  by  the  presence  of  multiple,  non-overlapping 
sites mediating the various potentiating effects of steroids. 
Here, we briefly describe the evidence supporting the two 
notions. 
  The strongest support for a single interaction site mediat-
ing the potentiating actions of steroids comes from mutage-
nesis experiments. Such studies have shown that mutation of 
the α1Q241 residue can affect all kinetic aspects of potentia-
tion by neurosteroids. For example, a receptor containing the 
α1Q241L mutation shows none of the kinetic effects on open 
and closed time distributions seen in the wild-type receptor 
in the presence of the neurosteroid allopregnanolone [4]. In 
the  binding  site  model  proposed  by  Hosie  et  al.  [20]  the 
α1Q241 residue forms a critical hydrogen bond with the C3 
hydroxyl  group.  Mutant  receptors  incapable  of  forming  a 
hydrogen  bond  (e.g.,  α1Q241L)  are  therefore  predicted  to 
lack all kinetic components if a single site, one defined by 
the α1Q241 residue, mediates potentiation. 
  The second piece of evidence supporting a single binding 
site for potentiating steroids comes from our work with the 
synthetic  steroid  analog  (3α,5α,11β)-3-hydroxy-11-methyl-
11-[[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenyl]methoxy]-  22    Current Neuropharmacology, 2010, Vol. 8, No. 1  Akk et al. 
pregnan-20-one (Fig. 3; 11-TFMPD3α5αP). A coapplication 
of  11-TFMPD3α5αP  with  GABA  modifies  the  open  and 
closed time distributions not unlike allopregnanolone  indi-
cating  that  the  synthetic  steroid  acts  on  the  same  kinetic 
processes. An examination of single-channel activity demon-
strates that in the presence of steroid, channel activity con-
sists of long-lived alternating periods of low and high open 
probability (Fig. 3A). The two modes of activity resemble 
channel  activity  observed  under  control  conditions  (in  the 
presence of GABA alone) and in the presence of GABA and 
a high dose of potentiating steroid such as allopregnanolone. 
Further investigation revealed that the mean duration of epi-
sodes with low open probability depends on the concentra-
tion  of  11-TFMPD3α5αP.  The  low  Po  episodes  become 
shorter as the concentration of steroid is increased (Fig. 3B). 
In contrast, the mean duration of high Po episodes remained 
essentially unchanged at all steroid concentrations. The find-
ings  could  be  explained  by  a  simple  model  where  steroid 
binding to the receptor enhances channel Po through a binary 
mode switch, and the high and low Po episodes reflect activ-
ity with and without associated steroid, respectively.  
  The  transitions between low  and high Po  episodes  can 
provide insight into steroid interaction with the receptor. If 
the individual kinetic effects of the steroid result from inde-
pendent interaction with multiple distinct sites, then the data 
should consist of episodes in which any number of the pa-
rameters is modified. For example, we should be able to de-
tect episodes in which the closed time distributions are modi-
fied but open time distributions remain like those in the pres-
ence of GABA alone. On the other hand, if steroid interac-
tion  with  a  single  site  mediates  all  changes  in  open  and 
closed time distributions, then the binding of steroid to the 
receptor would modify all parameters. The data presented in 
Table 1 indicate that within episodes of high open probabil-
ity all  three kinetic parameters contributing to potentiation 
were  modified.  In  contrast,  within  episodes  of  low  open 
probability none of the three kinetic parameters was signifi-
cantly different from that in the presence of GABA alone. 
Given the low probability of simultaneous, concerted bind-
ing to three distinct,  independent steroid binding sites,  the 
data  appear  to suggest that  the binding of a single steroid 
molecule elicits all three kinetic changes.  
  There are also several findings that cannot be easily ex-
plained  in  the  framework  of  a  single  interaction  site.  The 
most striking is the results from the experiments examining 
wild-type GABA-A receptor potentiation in the simultaneous 
presence  of  pregnanolone  and  etiocholanolone.  The  two 
steroids differ in their kinetic mechanisms of action. Preg-
nanolone  acts by  enhancing  the  mean duration  and preva-
lence of the long-lived open time component and decreasing 
the prevalence of long intracluster closed times, i.e., similar 
to allopregnanolone. Etiocholanolone only affects the preva-
lence  of  long  openings  [24].  The  difference  could  be  














Fig. (3). Mode switching in the presence of 11-TFMPD3α5αP. (A) A sample single-channel cluster from a cell-attached patch exposed to 
50 µM GABA + 50 nM 11-TFMPD3α5αP. For illustrative purposes channel openings are shown as upward deflections. The locations of 
mode switches between episodes of high and low open probability (Po) were selected by eye. (B) The mean duration of low Po episodes 
decreases as the steroid concentration is increased. (C) The probability of a receptor being in the low Po mode is reduced at higher steroid 
concentrations. The parameter was calculated as the mean fraction of time spent in the low Po mode. (D) Structure of the steroid analog 11-
TFMPD3α5αP. The data shown in the figure have not been published previously. Kinetic and Structural Determinants for GABA-A Receptor Potentiation  Current Neuropharmacology, 2010, Vol. 8, No. 1    23 
with the receptor within a single, common binding site, or by 
the steroids interacting with different subsets of three sepa-
rate sites. To attempt to distinguish between the two mecha-
nisms, we examined the effect of pregnanolone in the pres-
ence  of  etiocholanolone.  We  reasoned  that  if  a  single  site 
mediates all actions of the two steroids then the presence of 
etiocholanolone, a steroid with a single kinetic effect, would 
reduce the ability of pregnanolone to elicit a change in the 
mean  duration  of  OT3  and  the  prevalence  of  CT3.  In  es-
sence, etiocholanolone would act as a competitive inhibitor 
in this scenario. On the other hand, if the kinetic effects are 
mediated  by  steroid  interactions  with  distinct,  non-
overlapping sites then etiocholanolone should have no effect 
on  the  ability  of  pregnanolone  to  elicit  said  changes.  The 
single-channel  recordings  unequivocally  demonstrate  that 
etiocholanolone has no effect on the ability of pregnanolone 
to  potentiate  the  receptor  [24].  In  particular,  the  effect  of 
pregnanolone on the mean duration of OT3 and the preva-
lence  of  CT3  is  unchanged  in  the  presence  of  etiocho-
lanolone. These findings are most consistent with the con-
cept of multiple, non-overlapping steroid binding sites medi-
ating receptor potentiation [24]. 
  Additional evidence for the presence of multiple binding 
sites comes from the comparison of the concentration-effect 
relationships for the kinetic effects. A single site would be 
most  compatible  with  identical  concentration-effect  curves 
describing the kinetic effects. However, the data show that 
the synthetic neuroactive steroid (3α,5β,17β)-3-hydroxy-18-
norandrostane-17-carbonitrile  has  considerably  different 
potencies for the kinetic effects. The steroid modulates the 
prevalence  of  long  openings  and  long-lived  closed  times 
with EC50-s at approximately 20 nM. In contrast, the EC50 
for the change in the mean duration of long-lived openings is 
>10 µM [3].  
  We have previously shown that coapplication of ethanol 
can affect the ability of steroids to potentiate the α1β2γ2L 
GABA-A receptor [6, 8]. Interestingly, ethanol only affects 
changes in one of the kinetic parameters affected by steroids. 
The  concentration-effect  relationship  for  the  allopreg-
nanolone-induced increase in the mean duration of OT3 is 
shifted in the presence of 0.1 % ethanol by over 100-fold to 
lower steroid concentrations. The concentration-effect rela-
tionships for other kinetic parameters were found to be unaf-
fected [6]. In the model of multiple binding sites mediating 
steroid effects on the GABA-A receptor, these findings sug-
gest that ethanol selectively modulates the interaction of al-
lopregnanolone with the site that mediates the increase in the 
mean duration of long openings. But we note that a model in 
which steroids interact with a single site while ethanol selec-
tively modulates the gating / signal transduction element for 
one of the kinetic effects could also account for the findings. 
  The  GABA-A  receptor  contains  two  α  subunits  and 
hence  two  steroid  sites  as  defined  by  the  α1Q241  residue 
[20]. It  could be hypothesized  that  the  sites on  the  two  α 
subunits mediate distinct kinetic effects, e.g., steroid interac-
tion with one of the α subunits could lead to the effect on 
closed times, the other mediates the effects on open times. 
We tested this hypothesis by employing concatemeric recep-
tors, i.e., receptors in which two or more subunits are cova-
lently linked to each other by short linkers. We generated a 
γβα triple subunit and a βα tandem subunit. The Q241L mu-
tation was then selectively introduced to either of the two α 
subunits, and the ability of allopregnanolone to potentiate the 
mutated concatemeric receptor probed.  
  In  macroscopic  recordings,  receptors  containing  the 
α1Q241L mutation in both the γβα and βα constructs were 
insensitive to allopregnanolone. When only one of the two α 
subunits contained the mutation (as in γβαQ241L - βα or γβα 
- βαQ241L receptors), allopregnanolone remained capable of 
eliciting  potentiation,  albeit  with  somewhat  lower  potency 
[5,  11].  Notably,  the  steroid  concentration-effect  relation-
ships were  indistinguishable for  the two types of concate-
meric receptors containing a single mutated α subunit. Given 
the strong dependence of the degree of observed potentiation 
on  the  nature  of  the  kinetic  effects  mediating  potentiation 
(please  see  Fig.  2),  it  appeared  likely  that  similar  kinetic 
mechanisms  underlie  potentiation  in  both  mutant  con-
catemers.  
  We  were  able  to  conduct  single-channel  recordings  on 
the concatemeric receptor containing the α1Q241L mutation 
in the γβα construct (the expression level of γβα - βαQ241L 
receptors was too low for single-channel studies). The data 
indicate that the kinetic mechanisms of potentiation are simi-
lar in  the wild-type concatemeric receptor and in  the con-
catemeric receptor containing the α1Q241L mutation in the 
γβα  construct.  The  coapplication  of  allopregnanolone  with 
GABA  resulted  in  an  increase  in  the  mean  duration  and 
prevalence of long openings and a reduction in the preva-
lence of long closed times [5]. The data thus indicate that 
steroid  interactions  with  a  single  α  subunit  can  lead  to 
changes in the open and closed time distributions and medi-
ate potentiation by neuroactive steroids. 
Table 1.  Characteristics of the Two Modes of Activity in the Presence of the Steroid Analog 11-TFMPD3α5αP 
Origin of Activity  OT3 (ms)  Fraction OT3 (%)  Fraction CT3 (%) 
50 µM GABA  7 ± 3  13 ± 7  27 ± 6 
GABA + steroid (low Po episodes)  5 ± 1  19 ± 24  22 ± 5 
GABA + steroid (high Po episodes)  20 ± 3  32 ± 6  4 ± 2 
The table shows the mean duration and prevalence (fraction) of the longest-lived intracluster open time component (OT3), and the prevalence of the longest-lived intracluster closed 
time component (CT3) under control conditions (GABA only) and in the presence of the steroid 11-TFMPD3α5αP. The control data are from Li et al., 2007b. Single-channel clusters 
in the presence of 50 µM GABA and 50-1000 nM steroid (n = 4 patches) were broken into high and low Po episodes by eye, and the data from the two classes of episodes were 
analyzed separately. 24    Current Neuropharmacology, 2010, Vol. 8, No. 1  Akk et al. 
SUMMARY 
  In sum, the electrophysiological data indicate that poten-
tiating steroids act on the GABA-A receptor through specific 
changes in channel open and closed time properties. Many 
steroids,  including  the  endogenous  neurosteroid  allopreg-
nanolone act by modulating a total of three kinetic parame-
ters (mean duration and prevalence of OT3, and prevalence 
of CT3), while others can modulate only a subset of these 
parameters.  The  number  of  binding  sites  mediating  these 
effects is unclear at the moment. Some electrophysiological 
and  molecular  biological  data  support  a  single  site,  other 
findings are best accounted for by the presence of multiple 
sites. 
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